Our findings clearly showed that in the majority of normal tissues including prostate no detectable levels of PLAC1 could be found8,10 pointing to the possibility of PCa targeted therapy by employing anti-PLAC1 antibodies. The gene discussed is PLAC1; the disease is posterior cortical atrophy.